$NGNE News

Neurogene Announces Upcoming Presentations Highlighting Key Differentiators of NGN-401 for Rett Syndrome at the ESGCT 33rd Annual Congress

JP Morgan Initiates Coverage On Neurogene with Overweight Rating, Announces Price Target of $60

Neurogene 13G Filing Shows Jennison Associates Reports 11.1% Stake In Co. As Of Sept. 30

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Neurogene to Participate in H.C. Wainwright 28th Annual Global Investment Conference

Canaccord Genuity Maintains Buy on Neurogene, Lowers Price Target to $166

Guggenheim Maintains Buy on Neurogene, Raises Price Target to $81

HC Wainwright & Co. Maintains Buy on Neurogene, Lowers Price Target to $65

Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates

Neurogene Q2 EPS $(1.53) Misses $(1.39) Estimate

Neurogene Inc. Announces Pricing of $125 Million Public Offering

Neurogene Prices $125M Public Offering At $30/Share, $29.999999 Pre‑Funded Warrants

Neurogene Inc. (NGNE) Discusses Updated Phase 1/2 Data for NGN-401 Gene Therapy in Rett Syndrome - Slideshow

Neurogene Inc. Announces Proposed Public Offering

Neurogene Reveals Proposed Public Offering; No Size Disclosed

Neurogene Inc. (NGNE) Discusses Updated Phase 1/2 Data for NGN-401 Gene Therapy in Rett Syndrome Transcript

Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome

Neurogene Announces Updated Data From Phase 1/2 Clinical Trial Evaluating NGN-401 Gene Therapy For Treatment Of Females With Rett Syndrome

HC Wainwright & Co. Reiterates Buy on Neurogene, Maintains $70 Price Target

Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome